REPR 2018 Shareholders Meeting

Operating Highlights

  • Record net revenues – up 12.4%
  • Gross margin increased by 230 bps
  • Higher income and Adjusted EBITDA
  • Strong balance sheet with no debt and simple capital structure
  • Refreshed and strengthened management team
  • Added significant talent to the Board
  • February 2019: strategic plan launched to become the preferred drug delivery partner for specific infusion therapies in select markets
  • Vision 2022: $50M net revenue run rate, 70%+ gross margins, and 20% annual organic revenue growth through 2022

View Presentation